CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75.2% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Close

Trade Bristol Myers BMY

Sell
 Buy

BristolMyers live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

BristolMyers news

Emma Rose 2025 Jul 03, 08:35

US Economy on Stagflation Watch: Apollo Global Management's Outlook

Ava Grace 2025 Jul 03, 08:35

AI Podcast: Fresh Insights on Fed Rate Cut Timing - News in a New Way

Sophia Claire 2025 Jul 03, 07:35

S&P 500 Earnings Season to Test Rally Amidst Dim Outlook

Magnificent 7 earnings, US and Japan inflation due next week
Neil Wilson 2024 Jul 18, 16:00

Week ahead: Magnificent 7 earnings, 2 key inflation reports

Forex Indices
Wall Street earnings
Neil Wilson 2023 Oct 20, 10:00

Week ahead: Earnings bonanza, ECB decision & US inflation

Forex Indices
Megacap-tech-stocks.jpg
Neil Wilson 2023 Apr 21, 05:00

Week ahead: Megacap tech and 1-in-3 Dow components set to report

2022 Jul 24, 05:42

Week ahead: Fed to hike 100bps into a recession?

Latest news

Show more
Emma Rose 2025 Jul 15, 13:20

US Inflation & Tariffs: Will the Fed Hike Rates?

Emma Rose 2025 Jul 15, 12:20

Mnuchin Suggests Powell Resign from Fed Board After Chairmanship

Emma Rose 2025 Jul 15, 10:20

Trump Encouraged Ukraine to Strike Deep Inside Russia: A Shift in Strategy and Potential Escalation

liam james 2025 Jul 15, 09:20

Trump's Tariff Threat: Europe Scrambles to Avert a Full-Blown Trade War

Sophia Claire 2025 Jul 15, 06:20

US Inflation: CPI, Tariff Impact, and Federal Reserve Policy

liam james 2025 Jul 15, 06:20

Gold Price Outlook: Tariffs, Central Banks, and Supply Dynamics

Noah Lee 2025 Jul 15, 02:20

Bitcoin Breaks Consolidation, Surges Above $120K Amid Regulatory Optimism

Emma Rose 2025 Jul 15, 01:20

Kevin Hassett Emerges as Potential Fed Chair Under Trump: An Analysis

Info

Spread

0.29

Spread (%)

0.6292 %

Leverage

1:5

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Market open

Tuesday

13:31 - 19:59

Monday

13:31-19:59

Wednesday

13:31-19:59

Thursday

13:31-19:59

Friday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

96340680704

Shares Outstanding

2035079936

Earnings Date (Next)

2001-08-07

Div Yield

2025-08-01

Ex-Dividend Date

2025-07-03

Forward annual dividend rate

2.48

Forward annual dividend yield

0.0536

EPS

2.68

Learn more about this instrument

Bristol Myers Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

Latest Education Articles

Show more
Ghko B 2025 Jul 14, 16:00

NBIS Stock Jumped over 17%: What Happened to Nebius Group?

Shares Stocks
Ghko B 2025 Jul 14, 16:00

XLM Outperforms Bitcoin: Can Stellar Price (XLM) Reach $1?

Crypto
Frances Wang 2025 Jul 14, 16:00

Crypto CFD Trading for Beginners: Ethereum CFD, XRP CFD, Solana CFD

Crypto CFD Trading
Trustpilot